Effect of Highly Active Antiretroviral Therapy HAART on Lean Body Mass

Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2005-06-24

200

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

The purpose of this study is to determine whether HIV-positive patients with extremely low viral loads (level of HIV in the blood) have a greater gain in lean tissue during anti-HIV (antiretroviral) therapy than patients with higher viral loads. Many HIV-positive patients experience changes in body composition (muscle, fat, etc.) while on antiretroviral therapy. However, any weight gained while taking antiretrovirals is mostly fat. A patient's viral load may affect whether weight gained is a result of increased fat or increased muscle. A large-scale study is needed to closely evaluate the effects of antiretroviral therapy on body composition.

CONDITIONS

Brief Title

A Study to Evaluate the Effect of Anti-HIV Therapy on Lean Tissue (Muscle) in HIV-Positive Patients

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

Are enrolled in an adult AIDS clinical trial.
Are HIV-positive.
Have a viral load of at least 10,000 copies/ml.
Are expected to live at least 6 months.
Are at least 18 years old.

Exclusion Criteria

Patients will not be eligible for this study if they:

Have a history of diabetes requiring medication.
Have a history of heart disorders.
Have a fever, diarrhea, nausea, or a condition which makes it difficult to eat within the 14 days prior to study entry.
Have swelling due to any cause.
Are pregnant or breast-feeding.
Are receiving any therapy to increase your appetite or gain weight within 30 days prior to study entry.
Are receiving any therapy for a severe infection or medical illness within 14 days prior to study entry.
Are taking certain medications.